Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel - Top-Institutions - MDSpire

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

  • By

  • Noopur Raje

  • Kenneth Anderson

  • Hermann Einsele

  • Yvonne Efebera

  • Francesca Gay

  • Sarah P. Hammond

  • Alexander M. Lesokhin

  • Sagar Lonial

  • Heinz Ludwig

  • Philippe Moreau

  • Krina Patel

  • Karthik Ramasamy

  • Maria-Victoria Mateos

  • August 1, 2023

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Infectious Diseases

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Hematology
    • Oncology
    • Infectious Diseases

  • #5

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

Original Source(s)

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

  • by Noopur Raje, Kenneth Anderson, Hermann Einsele, Yvonne Efebera, Francesca Gay, Sarah P. Hammond, Alexander M. Lesokhin, Sagar Lonial, Heinz Ludwig, Philippe Moreau, Krina Patel, Karthik Ramasamy, Maria-Victoria Mateos

  • August 1, 2023

Related Content

This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

Lilly moves to acquire Kelonia, plus gene therapy for deafness approved

  • April 27, 2026

  • 6 min
Patient Awareness, Attitudes, and Preventive Practices Related to Venous Thromboembolism in Multiple Myeloma: A Cross-Sectional Analysis

Targeting CD38 Enzymatic Function in Antibody-Driven Immunotherapy for Multiple Myeloma: Insights from Basic Research